LightSphere Technologies

WHO WE ARE

At LightSphere Technologies, we are engineering the next revolution in healthcare: real-time, AI-powered molecular diagnostics that detect disease before symptoms appear.

We have assembled a Hall of Fame team of renowned scientists, AI innovators, and biotech leaders to commercialize the most sensitive biosensor ever developed.

OUR MISSION?

To push boundaries of what’s possible—detecting, diagnosing, and ultimately
curing disease at the molecular level.

INTEGRATED
MULTIMODAL CAUSAL AI

Scientifically proven In-Silico Phenotype Projection Technology integrates spatial transcriptomics, single cell RNA-seq, digital pathology, and nanoplasmonic biosensor data with cutting-edge conventional and quantum causal and generative AI/ML models to precisely identify therapeutically relevant molecular signals and regions of interest in heterogeneous human tissue samples.

THIS NOVEL
TECHNOLOGY ALLOWS

  • CLASS-FREE PATIENT SATISFACTION
  • EARLY DISEASE DETECTION
  • BIOMARKER DISCOVERY
  • DRUG DISCOVERY & DEVELOPMENT
  • DRUG REPOSITIONING

Working with a best-in-class team of AI data scientists, software engineers, and transnational scientists

Built with Biologically Relevant & Scientifically Validated Proprietary AI-Technology

SURFACE PLASMON ENHANCED BIOSENSING

Plasmonic Icon

Breakthrough plasmonic platform for surface enhanced biosensing with 10⁻¹⁰ electric field gain (40–120dB)

Biomarker Icon

100–1000 biomarker level sensitivity which enables sub femtomolar (10⁻¹⁵) measurement for less than 50µL sample volume

CMOS Icon

Fully CMOS compatible manufacturing process allows for transistor-like cost scaling

A Sub-mm PNN that
Diagnoses in Speed of Light

Plasmonic Neural Network (PNN) with nonlinear activation function plasmonic nodes supports universal approximation theorem and is causal AI/ML ready.

The low Ohmic loss hybrid plasmonic wave guiding structure enables scalability to large volumes.

All diagnostics stays within the optical domain, meaning the process is completed at the speed of light, enabling unparalleled computational efficiency.

MARKET

Today's biosensors are either too slow, too expensive, or too unreliable for real-time, high-accuracy diagnostics.

The healthcare industry is demanding next-generation sensing technologies that are ultra-senstivive, scalable, and AI-driven. This gap in the market represents an unparalleled opportunity.

With healthcare shifting toward precision medicine, real-time diagnostics and biosensing technology have become a trillion-dollar necessity. The intersection of AI, photonics, and biosensing is the next-gen wearables to clinical breakthroughs.

WHO BENEFITS?

  • HEALTHCARE & BIOTECH

    Medical diagnostics, disease monitoring, lab testing

  • PHARMACEUTICALS

    Drug discovery, biomarker detection

  • WEARABLE TECH & CONSUMER HEALTH

    Real-time health tracking

  • DEFENCE & INDUSTRIAL

    Chemical detection, environmental monitoring

  • ACADEMIC & RESEARCH LABS

    Precision sensing for molecular-level research

THE PARADIGM SHIFT

Three converging forces are reshaping biosensing

  • The rise of ai-driven diagnostics

  • The demand for ultra-fast, lab-grade detection outside of clinical settings

  • Breakthroughs in plasmonic nanoantennas allowing for unprecedented sensitivity and efficiency

LIGHTSPHERE IS POSITIONED AT THE CENTER OF THIS TRANSFORMATION

While traditional biosensors struggle with speed, power consumption, or accuracy, LightSphere's fusion of AI, plasmonics and photonics creates a new category altogether- one that competitors aren't even equipped to enter.

MAKE THE FUTURE POSSIBLE

CONTACT US